Atopic dermatitis (AD) is a common chronic, pruritic inflammatory skin disease that profoundly impacts patients’ quality of life. As the first FDA-approved topical JAK inhibitor, ruxolitinib 1.5% cream represents a novel therapeutic topical agent for the treatment of AD. The objective of this review is to summarize the efficacy and safety of ruxolitinib cream in patients with AD based on the available evidence. Overall, ruxolitinib cream demonstrated high efficacy and a favorable safety profile for treating atopic dermatitis.

No abstract

No abstract

No abstract

Irritant diaper dermatitis is a common dermatologic problem among infants and young children. Severe erosive presentations, although uncommon, are diagnostically challenging and can mimic non‐accidental trauma (NAT). Diagnosing inflicted injury and NAT where it does not exist can cause parental distress, yet failing to diagnose inflicted injury and NAT can result in re‐injury. We describe three cases of severe erosive diaper dermatitis in pediatric patients aged 2–6 years that were initially concerning for inflicted scald burn or neglect.